196 related articles for article (PubMed ID: 19630399)
1. In vivo structural activity and optimization studies of folate-tubulysin conjugates.
Reddy JA; Dorton R; Dawson A; Vetzel M; Parker N; Nicoson JS; Westrick E; Klein PJ; Wang Y; Vlahov IR; Leamon CP
Mol Pharm; 2009; 6(5):1518-25. PubMed ID: 19630399
[TBL] [Abstract][Full Text] [Related]
2. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
[TBL] [Abstract][Full Text] [Related]
3. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP
Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy.
Leamon CP; Reddy JA; Vlahov IR; Dorton R; Bloomfield A; Vetzel M; Klein PJ; Westrick E; Xu LC; Wang Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1151-1160. PubMed ID: 28451831
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.
Reddy JA; Dorton R; Westrick E; Dawson A; Smith T; Xu LC; Vetzel M; Kleindl P; Vlahov IR; Leamon CP
Cancer Res; 2007 May; 67(9):4434-42. PubMed ID: 17483358
[TBL] [Abstract][Full Text] [Related]
6. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.
Reddy JA; Westrick E; Vlahov I; Howard SJ; Santhapuram HK; Leamon CP
Cancer Chemother Pharmacol; 2006 Aug; 58(2):229-36. PubMed ID: 16331500
[TBL] [Abstract][Full Text] [Related]
7. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.
Leamon CP; Reddy JA; Vlahov IR; Westrick E; Parker N; Nicoson JS; Vetzel M
Int J Cancer; 2007 Oct; 121(7):1585-92. PubMed ID: 17551919
[TBL] [Abstract][Full Text] [Related]
8. [Folate receptor-mediated antitumor drugs].
Zhao J; Cao SL; Zheng XL; Zhao B
Yao Xue Xue Bao; 2009 Feb; 44(2):109-14. PubMed ID: 19408677
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate.
Leamon CP; Reddy JA; Vlahov IR; Kleindl PJ; Vetzel M; Westrick E
Bioconjug Chem; 2006; 17(5):1226-32. PubMed ID: 16984132
[TBL] [Abstract][Full Text] [Related]
10. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part II: Folic acid conjugates of tubulysins and their hydrazides.
Vlahov IR; Wang Y; Kleindl PJ; Leamon CP
Bioorg Med Chem Lett; 2008 Aug; 18(16):4558-61. PubMed ID: 18657420
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model.
Arote RB; Hwang SK; Lim HT; Kim TH; Jere D; Jiang HL; Kim YK; Cho MH; Cho CS
Biomaterials; 2010 Mar; 31(8):2435-45. PubMed ID: 20022105
[TBL] [Abstract][Full Text] [Related]
12. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity.
Schluep T; Gunawan P; Ma L; Jensen GS; Duringer J; Hinton S; Richter W; Hwang J
Clin Cancer Res; 2009 Jan; 15(1):181-9. PubMed ID: 19118045
[TBL] [Abstract][Full Text] [Related]
13. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers.
Dosio F; Milla P; Cattel L
Curr Opin Investig Drugs; 2010 Dec; 11(12):1424-33. PubMed ID: 21154124
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic.
Leamon CP; Reddy JA; Vlahov IR; Vetzel M; Parker N; Nicoson JS; Xu LC; Westrick E
Bioconjug Chem; 2005; 16(4):803-11. PubMed ID: 16029021
[TBL] [Abstract][Full Text] [Related]
15. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery.
Paulos CM; Reddy JA; Leamon CP; Turk MJ; Low PS
Mol Pharmacol; 2004 Dec; 66(6):1406-14. PubMed ID: 15371560
[TBL] [Abstract][Full Text] [Related]
16. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Müller C; Schubiger PA; Schibli R
Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
[TBL] [Abstract][Full Text] [Related]
17. Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy.
Sega EI; Lu Y; Ringor M; Leamon CP; Low PS
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):559-66. PubMed ID: 18411004
[TBL] [Abstract][Full Text] [Related]
18. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates.
Leamon CP; Reddy JA; Dorton R; Bloomfield A; Emsweller K; Parker N; Westrick E
J Pharmacol Exp Ther; 2008 Dec; 327(3):918-25. PubMed ID: 18791065
[TBL] [Abstract][Full Text] [Related]
19. Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.
Leamon CP; Vlahov IR; Reddy JA; Vetzel M; Santhapuram HK; You F; Bloomfield A; Dorton R; Nelson M; Kleindl P; Vaughn JF; Westrick E
Bioconjug Chem; 2014 Mar; 25(3):560-8. PubMed ID: 24564229
[TBL] [Abstract][Full Text] [Related]
20. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential.
Lu Y; You F; Vlahov I; Westrick E; Fan M; Low PS; Leamon CP
Mol Pharm; 2007; 4(5):695-706. PubMed ID: 17784727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]